Glucagon-like peptide-1 agonists

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 10 Jan 2012 English Publisher:BMJJournal:BMJ, volume 344, pages d7282-d7282 (issn: 0959-8138, eissn: 1468-5833,

Copyright policy )

Authors: Raj, Padwal;

doi: 10.1136/bmj.d7282

pmid: 22236410

Glucagon-like peptide-1 agonists

- Summary
- Subjects
- Metrics

Abstract

Cannot be recommended strictly for weight reduction until their benefits and risks are clarified

Keywords

Venoms, Liraglutide, Overweight, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide 1, Weight Loss, Receptors, Glucagon, Exenatide, Humans, Hypoglycemic Agents, Anti-Obesity Agents, Peptides

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	13
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%